Market Overview

UPDATE: Deutsche Bank Reiterates on Amgen Following Biosimilar Conference

Share:
Related AMGN
Has A Biotech Recovery Started Yet?
Short Sellers Dump Amgen And Baxalta
Sanofi: High Quality Product Portfolio But Risks Remain (Seeking Alpha)

In a report published Wednesday, Deutsche Bank analyst Robyn Karnauskas reiterated a Buy rating on Amgen (NASDAQ: AMGN), and raised the price target from $138.00 to $142.00.

In the report, Deutsche Bank noted, “We attended a biosimilar conference in order to learn more about the OPP'Y for Amgen. We came away with a greater understanding as to the impact of Biosimilars on AMGN's base biz & have adjusted our model accordingly. We also grew more comfortable in the Biosmilar opp'y for AMGN. We now include a probability adjusted Biosimilar revs beyond 2017 & note net/net biosimilars have a positive NPV to AMGN. Please ask for our Biosimilar APP.”

Amgen closed on Tuesday at $115.46.

Latest Ratings for AMGN

DateFirmActionFromTo
Apr 2016BMO CapitalInitiates Coverage onOutperform
Feb 2016CitigroupInitiates Coverage onNeutral
Feb 2016Argus ResearchMaintainsBuy

View More Analyst Ratings for AMGN
View the Latest Analyst Ratings

Posted-In: Deutsche Bank Robyn KarnauskasAnalyst Color Price Target Analyst Ratings

 

Related Articles (AMGN)

View Comments and Join the Discussion!